hypertension. The difference in all-cause and liver-related mortality suggests that this survival benefit may not be entirely liver related.

REFERENCES


O24 DURABILITY OF OBETICHOLIC ACID RESPONSE IN PBC PATIENTS WHO DID NOT ACHIEVE POISE TRIAL CRITERIA

1Gideon Hirschfield, 2Marco Carbone, 4David Jones, 1Bettina Hansen, 6Andreas Kremer, 7Michael Trauner, 3Alexander Liberman, 5Elizabeth Smott Malecha, 6Leigh MacConell, 1Toronto Centre for Liver Disease, Canada; 2University of Cambridge, UK; 3University of Milan Bicocca, Italy; 4Newcastle University, UK; 5IHPME, University of Toronto, Canada; 6Friedrich-Alexander-University Erlangen-Nürnberg, Germany; 7Medical University of Vienna, Austria; 8Intercept Pharmaceuticals, USA; 9Intercept Pharmaceuticals, UK

Introduction In clinical studies and in clinical practice, response to primary biliary cholangitis (PBC) treatment has been assessed using dichotomous biochemical response criteria. Although achieving these criteria may be associated with improved clinical outcomes, the benefit in patients (pts) with an incomplete response to treatment may be underestimated. This analysis assessed the extent and durability of obeticholic acid (OCA) response in pts with PBC not achieving the dichotomous primary endpoint in the phase 3 POISE study through 72 months of OCA treatment.

Methods Key inclusion criteria included PBC diagnosis, alkaline phosphatase (ALP) ≥1.67× upper limit of normal (ULN) and/or total bilirubin >ULN to <2× ULN, and on a stable dose of—or intolerant of—ursodeoxycholic acid (UDCA). During the 12-month double-blind (DB) phase, 216 pts were randomised to daily placebo, OCA 5–10 mg, or OCA 10 mg. This analysis pooled DB placebo (OCA baseline [BL] was open-label extension [OLE] day 0) and DB OCA pts to evaluate the efficacy and safety of up to 72 months of OCA treatment. Pts who achieved the POISE primary endpoint (ALP<1.67×ULN, with a ≥15% reduction from BL, and total bilirubin ≤ULN) 12 months from OCA BL were excluded. Values shown are mean (SD) unless otherwise specified. P values were based on paired t-tests.

Results Of the 193 pts enrolled in the OLE, 107 (55%) did not achieve the POISE criteria after 12 months of OCA treatment. Pts were 93% female, 91% Caucasian, 56 (10) years old at BL, and 91% received UDCA (15 [4] mg/kg/day). At BL, ALP was 356 (138) U/L and total bilirubin was 13 (8) µmol/L (>ULN in 18 pts [17%]). Despite not achieving the POISE criteria after 12 months of OCA, a significant and durable reduction was observed in ALP (p<0.01 at all time points) through 72 months of treatment (figure 1). Total bilirubin levels remained stable and near BL values within the normal range through the duration of treatment. Throughout the 6-year study period, the most common adverse events were pruritus (92 pts [86%]) and fatigue (33 pts [31%]), consistent with previous reports from POISE and expected PBC symptoms.

Conclusions Despite not achieving the POISE primary endpoint, these pts showed significant and sustained biochemical improvements.

O25 ALCOHOL RELATED LIVER DISEASE: DELAYED DIAGNOSIS AND MISSED OPPORTUNITIES FOR INTERVENTION

1Miss Rebecca Elleray*, 2Mohsen Subhani, 4Stephen Ryder, 6Jane Bethea. 1Public Health England, Nottingham, UK; 2University of Nottingham, Nottingham, UK; 3NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust, Nottingham, UK; 4Intercept Pharmaceuticals, USA

Introduction Death from alcohol related liver disease (ARLD) is preventable and increasing. Effective identification and brief